Dr. Dan Cao 曹丹
Chief Physician
Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and treatment of neuroendocrine tumors; multidisciplinary care for pancreatic, bile duct, liver, and gastrointestinal stromal tumors; comprehensive treatment of gastric, colorectal, and urogenital cancers.
Dr. Cao is a Chief Physician and Master’s Supervisor at West China Hospital, holding a medical doctorate jointly trained with the University of California, San Francisco. Dr. Cao has published over 30 SCI papers and leads research projects funded by the National Natural Science Foundation, National 863 Program, and CSCO-Merck Serono SCORE Fund.
Professional roles
- Vice Chair, Youth Committee of Chemotherapy Professional Committee, Sichuan Anti-Cancer Association
- Youth Member, Pancreatic Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Youth Member, Pancreatic Cancer Professional Committee, China Anti-Cancer Association
- Youth Editorial Board Member, Journal of Cancer Control and Treatment
Name order: in Chinese the family name comes first (Cao Dan). Papers usually list the name as Dan Cao or Cao D.
Selected publications
156 papers on PubMed matched by name and affiliation; 64 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Cancer Res, 2026 (senior author): Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trial. PubMed 42886001
- J Immunother Cancer, 2026 (senior author): Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort. PubMed 42731878
- Br J Cancer, 2026 (first author): Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). PubMed 42498744
- Front Oncol, 2026 (senior author): Correction: First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: study protocol for a prospective, multicenter, phase II study. PubMed 41847711
- Compr Physiol, 2026 (senior author): The Integrated Stress Response in Cancer: Paradox and Therapeutic Promise. PubMed 41566689
- Ther Adv Med Oncol, 2026 (senior author): Impact of adding recurrence/metastasis-directed therapy to systemic therapy in postoperative recurrent or metastatic pancreatic adenocarcinoma: a retrospective cohort study. PubMed 41624149
- J Transl Med, 2026 (senior author): Targeting NKG2D/NKG2DL axis in cancer immunotherapy: mechanisms and therapeutic applications. PubMed 41484787
- Front Cell Dev Biol, 2025 (senior author): A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy. PubMed 41210247
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion